Objective Limited economic evaluation data for rivaroxaban compared with standard of care (SoC) exists in China. The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban ...

Subcutaneous enoxaparin was used as bridging anticoagulant treatment according to a pre-established protocol. The global thromboembolic risk was carefully assessed in all patients. All patients were ...

Thus, results from ADVANCE-2 suggest a similar or greater efficacy of apixaban versus enoxaparin, when the European regimen of enoxaparin was used, for VTE prevention without increased bleeding.

Rondina et al. [30] examined medically ill patients who received weight-adjusted enoxaparin dosing for VTE prophylaxis.

Introduction Hospital-acquired thrombosis accounts for a large proportion of all venous thromboembolism (VTE), with significant morbidity and mortality. This subset of VTE can be reduced through ...